Pooled analysis by best confirmed response to trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+metastatic breast cancer (mBC) from DESTINY-Breast-01,-02, and-03

被引：0

作者：

Saura, Cristina

Cortes, Javier

Modi, Shanu

Kim, Sung-Bae

Hamilton, Erika P.

Hurvitz, Sara A.

Krop, Ian E.

Curigliano, Giuseppe

Iwata, Hiroji

Im, Seock-Ah

Herbolsheimer, Pia Maarit

Karnoub, Maha

Gambhire, Dhiraj

Egorov, Anton

Andre, Fabrice

机构：

[1] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[2] Quironsalud Grp, Int Breast Canc Ctr IBCC, Pangaea Oncol, Barcelona, Spain

[3] Mem Sloan Kettering Canc Ctr, New York, NY USA

[4] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea

[5] Sarah Cannon Res Inst, Nashville, TN USA

[6] Univ Washington, Sch Med, Seattle, WA USA

[7] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[8] Yale Canc Ctr, New Haven, CT USA

[9] Univ Milan, Milan, Italy

[10] IRCCS, European Inst Oncol, Milan, Italy

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Canc Res Inst,Natl Univ Hosp, Seoul, South Korea

[13] AstraZeneca, Gaithersburg, MD USA

[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[15] Daiichi Sankyo, Basking Ridge, NJ USA

[16] Univ Paris Saclay, Gustave Roussy, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1023

引用

页数：1

共 50 条

[21] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2+advanced/metastatic breast cancer (mBC) with or without brain metastases (BM): DESTINYBreast-12 primary results [J].

Lin, N. ;

Ciruelos, E. M. ;

Jerusalem, G. ;

Mueller, V. ;

Niikura, N. ;

Viale, G. ;

Bartsch, R. ;

Kurzeder, C. ;

Connolly, R. ;

Baron-Hay, S. E. ;

Cortes, M. Gion ;

Guarneri, V. ;

Bianchini, G. ;

Wildiers, H. ;

Escriva-de-Romani, S. ;

Prahladan, M. ;

Bridge, H. ;

Verma, S. ;

Harbeck, N. .

ANNALS OF ONCOLOGY, 2024, 35 :1211-1212

[22] Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial [J].

Epaillard, N. ;

Lusque, A. ;

Pistilli, B. ;

Andre, F. ;

Bachelot, T. ;

Pierga, J-Y. ;

Ducoulombier, A. ;

Jouannaud, C. ;

Viret, F. ;

Salabert, L. ;

Johnson, A. C. ;

Deluche, E. ;

Durando, X. ;

Petit, T. ;

Filleron, T. ;

Oukhatar, C. Mahier Ait ;

Dieras, V. C. ;

Mosele, M. F. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S656-S656

[23] A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC) [J].

Kumar, Prashanth Ashok ;

Sandhu, Michael ;

Sravanthi, Metlapalli Venkata ;

Kumar, Vishnu Charan Suresh ;

Benjamin, Sam .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[24] Trastuzumab deruxtecan (T-DXd, DS-8201) in HER2-positive metastatic breast cancer previously treated with T-DM1: DESTINY-Breast01 Study [J].

Krop, I. ;

Saura Manich, C. ;

Yamashita, T. ;

Park, Y. H. ;

Kim, S. -B. K. ;

Tamura, K. ;

Andre, F. ;

Iwata, H. ;

Ito, Y. ;

Tsurutani, J. ;

Sohn, J. ;

Denduluri, N. ;

Perrin, C. ;

Aogi, K. ;

Tokunaga, E. ;

Im, S. -A. ;

Lee, K. S. ;

Hurvitz, S. ;

Cortes, J. ;

Lee, C. ;

Chen, S. ;

Zhang, L. ;

Shahidi, J. ;

Yver, A. ;

Modi, S. .

SWISS MEDICAL WEEKLY, 2020, :25S-25S

[25] Impact of Serum HER2 Extracellular Domain in Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan (T-DXd) [J].

Nozawa, Kazuki ;

Kusudo, Maho ;

Kureyama, Nari ;

Nakakami, Akira ;

Komaki, Rie ;

Endo, Yuka ;

Kataoka, Ayumi ;

Kotani, Haruru ;

Yoshimura, Akiyo ;

Hattori, Masaya ;

Sawaki, Masataka ;

Iwata, Hiroji .

CANCER RESEARCH, 2024, 84 (09)

[26] A lower dose of trastuzumab deruxtecan (T-Dxd) is effective in controlling HER2-positive metastatic breast cancer [J].

Hsieh, Y. Pei .

ANNALS OF ONCOLOGY, 2024, 35 :S1394-S1394

[27] Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) [J].

Tarantino, P. ;

Kim, S. E. ;

Chan, N. N. N. ;

Hughes, M. E. ;

Smith, K. ;

D'Amico, O. R. ;

Kusmick, R. ;

Pereslete, A. M. ;

Alder, L. ;

Anders, C. ;

Morganti, S. ;

Garrido-Castro, A. C. ;

Lorusso, P. ;

Lustberg, M. ;

Sammons, S. ;

Lin, N. ;

Li, T. ;

Tayob, N. ;

Rimm, D. ;

Tolaney, S. M. .

ANNALS OF ONCOLOGY, 2024, 35 :S384-S385

[28] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02) [J].

Meric-Bernstam, Funda ;

Kim, Seung Tae ;

Parinyanitikul, Napa ;

Moreno, Alberto ;

Lin, Chia-Chi ;

Gornastolev, Dmitry ;

Chindaprasirt, Jarin ;

Lugowska, Iwona A. ;

Stroyakovskiy, Daniil ;

Jassem, Jacek ;

Harrison, Michelle L. ;

Ostwal, Vikas S. ;

Michelini, Flavia ;

Jung, Lindsey ;

Kuptsova-Clarkson, Nataliya ;

Puvvada, Soham D. ;

Gan, Hui Kong .

JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

[29] TRASTUZUMAB (T) TOLERABILITY AND ACTIVITY IN HER2+METASTATIC BREAST CANCER (MBC) PATIENTS (PTS) AGED ≥65 YEARS [J].

Bernardi, A. ;

Zucchini, G. ;

Rosati, M. ;

Rubino, D. ;

Quercia, S. ;

Cacciari, N. ;

Zamagni, C. ;

Martoni, A. A. .

ANNALS OF ONCOLOGY, 2010, 21 :102-102

[30] Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. [J].

Modi, Shanu ;

Jacot, William ;

Yamashita, Toshinari ;

Sohn, Joohyuk ;

Vidal, Maria ;

Tokunaga, Eriko ;

Tsurutani, Junji ;

Ueno, Naoto T. ;

Chae, Yee Soo ;

Lee, Keun Seok ;

Niikura, Naoki ;

Park, Yeon Hee ;

Wang, Xiaojia ;

Xu, Binghe ;

Gambhire, Dhiraj ;

Yung, Lotus ;

Meinhardt, Gerold ;

Wang, Yibin ;

Harbeck, Nadia ;

Cameron, David A. .

JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)

← 1 2 3 4 5 →